Oliver Sartor MD
Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, MinnesotaDr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
Disclosures
CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.
Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.
Recent Contributions to PracticeUpdate:
- Contextualizing PROSPER Data: Recommendations From ASCO GU 2018
- Radium-223 in mCRPC: Updates From ASCO GU 2018
- Patient-Reported Outcomes Following Abiraterone Acetate Plus Prednisone Added to ADT for Newly Diagnosed Metastatic Castration-Naïve Prostate Cancer
- 2017 Top Stories in Advanced Prostate Cancer: LATITUDE and STAMPEDE
- ADT No Longer the Standard of Care for Metastatic Prostate Cancer: An Expert Roundtable
- Integrating Genetic Testing for Prostate Cancer in Clinical Practice
- My Approach to Utilizing Molecular Markers in Prostate Cancer
- The New Standard of Care? Abiraterone in Metastatic Prostate Cancer
- Practice Changers in Advanced Prostate Cancer From ASCO 2017: STAMPEDE, LATITUDE vis-à-vis CHAARTED
- ASCO 2017: Abstract Recommendations From Dr. Oliver Sartor—Prostate Cancer